References
1. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, Mugo NR, Wald A, Corey L, Donnell D, Campbell MS, Mullins JI, Celum C, Partners in Prevention HSVHIVTST. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med2011; 3 (77): 77ra29.
2. John GC, Nduati RW, Mbori-Ngacha DA, Richardson BA, Panteleeff D, Mwatha A, Overbaugh J, Bwayo J, Ndinya-Achola JO, Kreiss JK. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections. J Infect Dis 2001;183 (2): 206-12.
3. Taylor S, Boffito M, Vernazza PL. Antiretroviral therapy to reduce the sexual transmission of HIV. J HIV Ther 2003; 8 (3): 55-66.
4. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.Sci Transl Med 2011; 3 (112): 112re4.
5. Nicol MR, Corbino JA, Cottrell ML. Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention. J Clin Pharmacol2018; 58 (11): 1381-95.
6. Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, Shaheen NJ, Patterson KB, Kashuba AD. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. J Acquir Immune Defic Syndr 2016; 72 (5): 498-506.
7. Bennetto-Hood C, Johnson VA, King JR, Hoesley CJ, Acosta EP. Novel methodology for antiretroviral quantitation in the female genital tract.HIV Clin Trials 2009; 10 (3): 193-9.
8. Amara AB, Else LJ, Tjia J, Olagunju A, Puls RL, Khoo S, Back DJ. A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry.Ther Drug Monit 2015; 37 (2): 220-8.
9. Olagunju A, Bolaji OO, Amara A, Waitt C, Else L, Soyinka J, Adeagbo B, Adejuyigbe E, Siccardi M, Back D, Owen A, Khoo S. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.J Antimicrob Chemother 2015; 70 (2): 555-61.
10. FDA. Food and Drug Administration. Guidance for Industry. Bioanalytical Method Validation 2018. Maryland: Food and Drug Administration, US Department of Health and Human Services. Available from: https://www.fda.gov/media/70858/download.
11. Olagunju A, Anweh D, Okafor O, Dickinson L, Richman D, Owen A, Adejuyigbe E. Viral and antiretroviral dynamics in HIV mother-to-child transmission fluids (VADICT) – Protocol and data analysis plan for a cohort study [version 1; referees: awaiting peer review].Wellcome Open Res 2019; 4 (34).
12. Duwal S, Seeler D, Dickinson L, Khoo S, von Kleist M. The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis. Front Pharmacol 2019; 10 : 199.
13. Duwal S, Dickinson L, Khoo S, von Kleist M. Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis. Plos Comput Biol 2019; 15 (1): e1006740.
14. Kwara A, Delong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46 (5): 719-25.
15. Min SS, Corbett AH, Rezk N, Cu-Uvin S, Fiscus SA, Petch L, Cohen MS, Kashuba AD. Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women.J Acquir Immune Defic Syndr 2004; 37 (5): 1577-80.
16. Usala SJ, Schumacher GF. Volumetric self-sampling of cervicovaginal fluid: a new approach to ovulation timing. Fertil Steril 1983;39 (3): 304-9.
17. Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet 2012;51 (12): 809-22.
18. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16 (8): 1149-67.
19. Adams JL, Patterson KB, Prince HM, Sykes C, Greener BN, Dumond JB, Kashuba AD. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther 2013;18 (8): 1005-13.
20. Le MP, Belarbi L, Chaix ML, Dulioust E, Mahjoub N, Salmon D, Viard JP, Duvivier C, Peytavin G, Launay O, Ghosn J. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. J Antimicrob Chemother2017; 72 (11): 3167-71.
21. Van Niekerk N, Nuttall J, Zeiser S, Nel A. Population pharmacokinetic modelling of dapivirine. AIDS Res Hum Retroviruses 2014; 30 : A38–A39.
22. Yang K-H, Schwartz J, Sykes C, Doncel G, Kashuba A. Population pharmacokinetic model of vaginal tenofovir 1% gel in the cervicovaginal fluid. AIDS Res Hum Retroviruses 2014; 30 : A38–A38.
23. Katz DF, Yuan A, Gao Y. Vaginal drug distribution modeling.Adv Drug Deliv Rev 2015; 92 : 2-13.
24. Thompson CG, Sedykh A, Nicol MR, Muratov E, Fourches D, Tropsha A, Kashuba AD. Short communication: cheminformatics analysis to identify predictors of antiviral drug penetration into the female genital tract.AIDS Res Hum Retroviruses 2014; 30 (11): 1058-64.
25. Parsons TL, Emory JF, Seserko LA, Aung WS, Marzinke MA. Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis. J Pharm Biomed Anal 2014; 98 : 407-16.